These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19355806)

  • 1. The impact of residual CVD risk in the managed care setting.
    Cziraky MJ
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S74-80. PubMed ID: 19355806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
    Broncel M; Balcerak M; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of niacin and simvastatin combination therapy.
    Bays H
    Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
    Charland SL; Malone DC
    Curr Med Res Opin; 2010 Feb; 26(2):365-75. PubMed ID: 19995326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
    Vo AN; Kashyap ML
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid management in the geriatric patient.
    Nair AP; Darrow B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with recurrent coronary events among patients with cardiovascular disease.
    McConnell KJ; Olson KL; Delate T; Merenich JA;
    Pharmacotherapy; 2009 Aug; 29(8):906-13. PubMed ID: 19637943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I have had trouble controlling my cholesterol with a statin alone. Should I consider prescription niacin?
    Johns Hopkins Med Lett Health After 50; 2010 Feb; 21(12):8. PubMed ID: 20344817
    [No Abstract]   [Full Text] [Related]  

  • 14. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG; Zhao XQ
    Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy in the management of mixed dyslipidaemia.
    Cannon CP
    J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidant versus lipid-altering therapy--some answers, more questions.
    Freedman JE
    N Engl J Med; 2001 Nov; 345(22):1636-7. PubMed ID: 11757512
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY
    Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin-simvastatin combination benefits patients with coronary artery disease.
    SoRelle R
    Circulation; 2001 Dec; 104(24):E9050-60. PubMed ID: 11764785
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence.
    Balu S; Simko RJ; Quimbo RM; Cziraky MJ
    Curr Med Res Opin; 2009 Nov; 25(11):2765-75. PubMed ID: 19785511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.